Business News
-

Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia
Ahmedabad : Zydus, a leading, discovery-based, global pharmaceutical company today announced that the USFDA has granted Orphan Drug Designation (ODD) to Desidustat, a novel oral HIF-PHI, for the treatment of beta-thalassemia. The USFDA’s Office of…
-

Britannia’s Consolidated Sales for the quarter grew 4% while Net profit grew 23%
Mumbai : Britannia’s Consolidated Sales for the Quarter ended 30th September 2025 stands at Rs 4,752 Crores, growing 4.1% and Net Profit stands at Rs 655 Crores, growing 23% on a year-on-year basis. Commenting on…
-

Shriram General Insurance’s GWP Up 28%, Net Profit rises 6% in H1 FY26
Key Highlights of H1 FY26: Jaipur : Shriram General Insurance Company (SGI) delivered a strong performance in the first half of fiscal 2026, driven by sustained momentum in its motor insurance portfolio. The company recorded a 28%…
-

Cure.fit Strengthens Partnership with Unicommerce
Adopts UniReco for Automated Payment Reconciliation and Revenue Accuracy New Delhi : Curefit, India’s leading fitness and wellness platform, has expanded its partnership with Unicommerce by adopting UniReco, an automated payment reconciliation solution that enhances financial…
-

Concord Control Systems Limited reports ~ 85 % YoY Growth in H1 FY26 TotalPAT
Lucknow : Concord Control Systems Limited (BSE: CNCRD | 543619), India’s leading manufacturer of embedded electronic systems and critical electronic solutions, today announced its unaudited financial results for the half year ended September 30th, 2025.…
-

Strides Delivers a Robust Q2FY26 with Highest Ever Quarterly EPS Q2FY26 Operational PAT at ₹1,403m and EPS at ₹15.2, Grew 84% YoY
Q2 FY2026 Performance Highlights Bangalore : Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025. Financial Highlights (In…



